# FogPharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fogpharma

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.fogpharma.com
- Total disclosed funding: $380M
- Latest round: Series E (Mar 1, 2024)
- Investors on record: 31

## About

Based in Massachusetts, US, and founded in 2016, Fog Pharmaceuticals, Inc. operates as a biotechnology company that focuses on developing cell-penetrating miniprotein medicines for the treatment of cancer. The company was founded by its CEO, Greg Verdine. In March 2024, FogPharma raised USD 145 million in Series E funding led by Nextech, with participation from ARCH Venture Partners, Fidelity Investments, GV, Cormorant Asset Management, T. Rowe Price, Farallon Capital Management, VenBio Partners, and Milky Way Ventures. 

The company provides CPMPs (Cell-penetrating mini proteins) that target cancer-causing proteins inside cancer cells. The CPMPs platform includes Helicons, Pro-locks, and Griptides.

Fog Pharmaceuticals plans to use the proceeds from its March 2024 funding to advance its first-and-only-in-class direct ß-catenin antagonist into clinical development to potentially address 20% or more of all cancers.

## Funding rounds

- Series E, Mar 1, 2024, $145M — ARCH Venture Partners, General Catalyst Partners, Invus [DUP], Marshall Wace, Nextech, Fidelity Investments, GV, Foresite Capital, VenBio, RA Capital Management, Rock Springs Capital, Cormorant Asset Management, Farallon Capital Management, Milky Way Ventures, Samsara BioCapital, T Rowe Price Advisory Services, Catalio Capital Management, Sixty Degree Capital, SymBiosis Capital Management
- Series D, Nov 17, 2022, $178M — ARCH Venture Partners, T Rowe Price, HBM Partners, Invus [DUP], Fidelity Investments, GV, Casdin Capital, VenBio, Deerfield Management, Cormorant Asset Management, Farallon Capital Management, Milky Way Ventures, PagsGroup
- Series C, Jul 16, 2021, $3.6M — HBM Partners
- Series C, Dec 22, 2020, $23M — T Rowe Price, HBM Partners, Invus [DUP], GV, Casdin Capital, Blue Pool Capital, VenBio, Deerfield Management, Cormorant Asset Management, Farallon Capital Management, 6 Dimensions Capital, PagsGroup
- Series B, May 15, 2018, $31M — GV, Boyu Capital, Leerink Partners, Blue Pool Capital, Horizons Ventures, Deerfield Management, 6 Dimensions Capital, Nan Fung Group, Wuxi AppTec Group

## Investors

- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C, Series D, Series E
- Boyu Capital (https://capitalatlas.ai/funds/boyu-capital) — Series B
- Leerink Partners — Series B
- Blue Pool Capital (https://capitalatlas.ai/funds/blue-pool-capital) — Series B, Series C
- Horizons Ventures — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B, Series C, Series D
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series B, Series C
- Nan Fung Group — Series B
- Wuxi AppTec Group — Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C, Series D
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C, Series D
- Invus [DUP] — Series C, Series D, Series E
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series C, Series D
- VenBio (https://capitalatlas.ai/funds/venbio) — Series C, Series D, Series E
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C, Series D, Series E
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series C, Series D, Series E
- PagsGroup — Series C, Series D
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series D, Series E
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series D, Series E
- Milky Way Ventures (https://capitalatlas.ai/funds/milky-way-ventures) — Series D, Series E
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series E
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series E
- Nextech (https://capitalatlas.ai/funds/nextech) — Series E
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series E
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series E
- Rock Springs Capital — Series E
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series E
- T Rowe Price Advisory Services — Series E
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series E
- Sixty Degree Capital (https://capitalatlas.ai/funds/sixty-degree-capital) — Series E
- SymBiosis Capital Management (https://capitalatlas.ai/funds/symbiosis-capital-management) — Series E